ANUHPHRNSEAnuh Pharma LimitedHighNeutral
Announced Wed, 20 May · 23:48 IST

Anuh Pharma Limited has informed the Exchange regarding '66Th Annual General Meeting Will Be Held On Wednesday, 12Th August, 2026.'.

Revenue Growth 20pctPat NegativeEbitda Margin CompressionResults View source PDF

ANUHPHR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-6.2%1-day move
₹81.50
prior close
₹80.81
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-3.5-3.5-4.3-4.6-6.2-6.3-6.1-6.1-6.1-7.5-2.5-3.2-1.4
Up moveDown movePending
AI summary

Anuh Pharma Limited reported FY26 revenue of Rs. 77,165.74 Lakhs, up 16.6% from Rs. 66,151.49 Lakhs in FY25, showing solid topline growth. However, profit after tax declined 13.3% to Rs. 4,104.61 Lakhs from Rs. 4,735.19 Lakhs, while EBITDA fell to Rs. 6,607.59 Lakhs from Rs. 7,036.40 Lakhs. EBITDA margin compressed from 10.64% to 8.56%, indicating margin pressure. Operating cash flow turned negative at Rs. -301.16 Lakhs versus positive Rs. 3,712.47 Lakhs in FY25, a significant deterioration. The Board recommended a dividend of Rs. 1.50 per share (30% payout). Statutory auditors Jayantilal Thakkar & Co. issued an unmodified opinion. Nine promoter group shareholders (0.95% stake) have sought re-classification to public category. The 66th AGM is scheduled for August 12, 2026.

Likely market impact

The company shows revenue growth but declining profitability and negative operating cash flow, which may concern investors. The bonus share issuance (1:1 in July 2025) doubled share count, reducing EPS to Rs. 4.10 from Rs. 4.72. The margin compression and cash flow deterioration are red flags despite clean audit opinion.